On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm ...

JPMorgan pointed out that IL-33 was never a key component of its model, though. The company stressed that, even without accounting for any pipeline contribution, Dupixent, Eylea, and Regeneron ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday,Benzinga ...

Regeneron (REGN) shares trended higher pre-market Friday after JPMorgan upgraded it, noting several key catalysts in 2023, including the launch of high-dose Eylea. Read the full story here.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

The JPMorgan Healthcare Conference currently under way in San Francisco is arguably the most important event of the entire year for the health care sector. This is one of the rarest opportunities ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 40th Annual JPMorgan Virtual Healthcare Conference January 10, 2022 10:30 AM ETCompany ParticipantsLen ...

TARRYTOWN, N.Y., Jan. 7, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will provide a strategic business update to the investor community today at the 37 th Annual J.P ...

--Regeneron Pharmaceuticals, Inc. will webcast its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m ...

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday ...